Promotion of angiogenesis by mesenchymal stem cell exosomes: a new frontier in cutaneous wound healing
British Medical Bulletin · 02.01.2026 · 157 (1)
DOI: 10.1093/bmb/ldag003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Medical Bulletin, online erschienen am 02.02.2026. Verfasst von Mohammad Kalhorniagolkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, 71441-11731, Iran. Hauptthemen laut MEDLINE: Exosomes, Wound Healing, Neovascularization, Physiologic, Mesenchymal Stem Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 240 Literaturangaben.
Themen: Wundversorgung
Abstract (Originalsprache)
Introduction Angiogenesis plays a pivotal role in cutaneous wound healing by restoring vascular supply to regenerating tissues. Mesenchymal stem cell–derived exosomes (MSC-exosomes) are emerging as potent acellular mediators of angiogenesis, thanks to their cargo of bioactive molecules and immunomodulatory effects. Sources of data This review synthesizes recent findings from in vivo and in vitro studies, including preclinical models of diabetic wounds, ischemic injuries, and burn healing. It draws upon peer-reviewed articles published in biomedical journals, with a focus on the mechanisms and efficacy of MSC-exosomes. Areas of agreement MSC-derived exosomes enhance endothelial cell proliferation, migration, and tube formation. Their ability to activate pro-angiogenic signaling pathways, such as Wnt/β-catenin, AKT/eNOS, and angiopoietin/TIE2, is widely accepted. Additionally, their low immunogenicity, enhanced stability, and potential for bioengineered delivery systems are recognized advantages over other angiogenic therapies. Areas of controversy Challenges persist regarding the standardization of exosome isolation, characterization, and large-scale production. Debate also exists about their long-term safety and therapeutic consistency across MSC sources. Growing points Incorporation of MSC-exosomes into hydrogels and scaffolds offers promising controlled delivery systems that enhance angiogenic efficacy. Preconditioning MSCs (e.g. with hypoxia or pharmacological agents) further improves the pro-angiogenic potency of exosomes. Areas timely for developing research Future efforts should prioritize clinical translation by developing GMP-compliant production protocols, optimizing delivery strategies, and conducting rigorous clinical trials to assess safety, dosing, and therapeutic efficacy across diverse wound types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, 71441-11731, Iran.
- Department of Orthopaedic and Trauma Surgery, Faculty of Medicine and Psychology, Sant'Andrea Hospital Sapienza University of Rome, Via Di Grottarossa, 00189 Rome, Italy.
- Centre for Sport and Exercise Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 275 Bancroft Road, E1 4DG London, United Kingdom.
- Faculty of Medicine, School of Pharmacy and Bioengineering, Keele University, Thurnburrow Drive, Stoke on Trent ST4 7QB, United Kingdom.
ORCID-Profile: Mohammad Kalhorniagolkar, Ahmad Oryan, Nicola Maffulli
Zitieren
APA
Kalhorniagolkar, M., Oryan, A., & Maffulli, N. (2026). Promotion of angiogenesis by mesenchymal stem cell exosomes: a new frontier in cutaneous wound healing. British Medical Bulletin, 157(1). https://doi.org/10.1093/bmb/ldag003
Vancouver
Kalhorniagolkar M, Oryan A, Maffulli N. Promotion of angiogenesis by mesenchymal stem cell exosomes: a new frontier in cutaneous wound healing. British Medical Bulletin. 2026;157(1). doi:10.1093/bmb/ldag003
BibTeX
@article{Kalhorniagolkar2026,
author = {Kalhorniagolkar, Mohammad and Oryan, Ahmad and Maffulli, Nicola},
title = {Promotion of angiogenesis by mesenchymal stem cell exosomes: a new frontier in cutaneous wound healing},
journal = {British Medical Bulletin},
year = {2026},
volume = {157},
number = {1},
doi = {10.1093/bmb/ldag003}
}
EUVIMED